586.48
price down icon0.80%   -4.72
after-market アフターアワーズ: 586.48
loading
前日終値:
$591.20
開ける:
$581.94
24時間の取引高:
402.48K
Relative Volume:
0.72
時価総額:
$25.15B
収益:
$3.17B
当期純損益:
$1.29B
株価収益率:
21.65
EPS:
27.0947
ネットキャッシュフロー:
$1.01B
1週間 パフォーマンス:
+4.08%
1か月 パフォーマンス:
+20.79%
6か月 パフォーマンス:
+3.05%
1年 パフォーマンス:
+41.20%
1日の値動き範囲:
Value
$581.88
$589.19
1週間の範囲:
Value
$562.86
$593.50
52週間の値動き範囲:
Value
$409.07
$609.35

United Therapeutics Corp Stock (UTHR) Company Profile

Name
名前
United Therapeutics Corp
Name
セクター
Healthcare (1052)
Name
電話
(301) 608-9292
Name
住所
1000 SPRING ST, SILVER SPRING, MD
Name
職員
1,400
Name
Twitter
Name
次回の収益日
2026-11-04
Name
最新のSEC提出書
Name
UTHR's Discussions on Twitter

Compare UTHR vs TAK, TEVA, HLN, ZTS

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
UTHR icon
UTHR
United Therapeutics Corp
586.48 25.15B 3.17B 1.29B 1.01B 27.09
TAK icon
TAK
Takeda Pharmaceutical Co Adr
20.15 64.37B 29.91B 1.30B 3.49B 0.4056
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
39.97 46.62B 17.53B 1.58B 444.18M 1.3457
HLN icon
HLN
Haleon Plc Adr
10.00 43.98B 14.54B 2.22B 2.58B 0.4871
ZTS icon
ZTS
Zoetis Inc
77.80 32.15B 9.51B 2.64B 2.14B 6.0361

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-10-01 アップグレード BTIG Research Neutral → Buy
2026-09-24 開始されました Goldman Sell
2026-05-07 アップグレード Wells Fargo Equal Weight → Overweight
2026-04-10 開始されました Raymond James Outperform
2025-10-20 開始されました Wells Fargo Underweight
2025-09-26 開始されました RBC Capital Mkts Outperform
2025-06-02 開始されました Cantor Fitzgerald Overweight
2025-04-25 ダウングレード Wells Fargo Overweight → Equal Weight
2025-04-21 アップグレード BofA Securities Underperform → Neutral
2024-07-11 ダウングレード Morgan Stanley Overweight → Equal-Weight
2024-02-12 アップグレード Goldman Sell → Neutral
2024-02-05 開始されました Leerink Partners Outperform
2023-12-08 開始されました Wells Fargo Overweight
2022-12-06 開始されました UBS Buy
2022-12-05 開始されました Goldman Sell
2022-10-11 開始されました Morgan Stanley Overweight
2022-09-20 繰り返されました BofA Securities Underperform
2022-09-19 再開されました Wedbush Outperform
2022-02-11 開始されました BTIG Research Neutral
2021-07-14 アップグレード Argus Hold → Buy
2021-04-26 再開されました Credit Suisse Outperform
2021-02-01 アップグレード H.C. Wainwright Neutral → Buy
2020-09-14 再開されました JP Morgan Overweight
2020-06-25 繰り返されました H.C. Wainwright Neutral
2020-03-10 アップグレード Jefferies Hold → Buy
2020-02-27 アップグレード Cowen Market Perform → Outperform
2020-01-31 アップグレード JP Morgan Neutral → Overweight
2019-12-03 開始されました BofA/Merrill Underperform
2019-08-01 アップグレード Jefferies Underperform → Hold
2019-08-01 アップグレード Ladenburg Thalmann Neutral → Buy
2019-07-01 アップグレード Credit Suisse Neutral → Outperform
2019-05-17 アップグレード UBS Sell → Neutral
2019-05-09 アップグレード Credit Suisse Underperform → Neutral
2018-10-12 アップグレード Standpoint Research Hold → Buy
2018-08-08 ダウングレード Credit Suisse Neutral → Underperform
2018-04-03 アップグレード Credit Suisse Underperform → Neutral
2018-02-22 繰り返されました Barclays Underweight
2018-01-18 再開されました Credit Suisse Underperform
2017-12-27 繰り返されました Wedbush Outperform
2017-04-27 繰り返されました Wedbush Outperform
2017-03-30 開始されました UBS Sell
2017-03-16 開始されました Credit Suisse Underperform
すべてを表示

United Therapeutics Corp (UTHR) 最新ニュース

pulisher
04:31 AM

Options exercised at $117.76 a share accompanied sales by United Therapeutics (UTHR) CEO's trusts. - Stock Titan

04:31 AM
pulisher
10:30 AM

$100 Invested In United Therapeutics 15 Years Ago Would Be Worth This Much Today - Benzinga

10:30 AM
pulisher
07:22 AM

United Therapeutics Rising Ahead of Next Earnings Report - FXEmpire

07:22 AM
pulisher
07:02 AM

FDA clears United Therapeutics to begin Treprostinil-Iloprost trial - StreetInsider

07:02 AM
pulisher
Oct 27, 2026

CEO trusts exercised $117.76 options and sold 9,500 shares in United Therapeutics (UTHR). - Stock Titan

Oct 27, 2026
pulisher
Oct 27, 2026

S&P 500 Futures Up in Premarket Trading; MSG Sports, United Therapeutics Lag - Barron's

Oct 27, 2026
pulisher
Oct 26, 2026

United Therapeutics CEO sells $5.5M in stock By Investing.com - Investing.com Nigeria

Oct 26, 2026
pulisher
Oct 26, 2026

Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 23 October - Investing.com Nigeria

Oct 26, 2026
pulisher
Oct 26, 2026

United Therapeutics CEO sells $5.5M in stock - Investing.com

Oct 26, 2026
pulisher
Oct 26, 2026

After exercising options at $117.76, United Therapeutics (UTHR) CEO trusts sell 9,500 shares. - Stock Titan

Oct 26, 2026
pulisher
Oct 25, 2026

United Therapeutics (NDQ:UNTR): The Only Company Attempting Xenotransplantation At Scale! - Stocks Down Under

Oct 25, 2026
pulisher
Oct 24, 2026

U.S. transgender billionaire Martine Rothblatt sells $5.5 million in United Therapeutics stock - Billionaires.Africa

Oct 24, 2026
pulisher
Oct 24, 2026

Martine Rothblatt, United Therapeutics CEO, sells $5.5M in stock - Investing.com

Oct 24, 2026
pulisher
Oct 23, 2026

United Therapeutics Gets FDA Clearance to Start Phase 2 SUMMIT Trial of Treprostinil Soft Mist Inhaler in PH-COPD - BioBuzz

Oct 23, 2026
pulisher
Oct 23, 2026

United Therapeutics to build a $9 million hangar at Rochester's airport - Post Bulletin

Oct 23, 2026
pulisher
Oct 22, 2026

United Therapeutics CEO Rothblatt sells $5.3m in UTHR stock - Investing.com

Oct 22, 2026
pulisher
Oct 22, 2026

Is United Therapeutics Corp (UTHR) Overvalued After 3.8% Rally? - GuruFocus

Oct 22, 2026
pulisher
Oct 22, 2026

Generation Park lands new facility to scale xeno-organ production - InnovationMap

Oct 22, 2026
pulisher
Oct 22, 2026

United Therapeutics authorizes $2 billion buyback program - Investing.com

Oct 22, 2026
pulisher
Oct 22, 2026

United Therapeutics Authorizes Up to $2 Billion Share Repurchase - TradingView

Oct 22, 2026
pulisher
Oct 22, 2026

United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization - Yahoo Finance

Oct 22, 2026
pulisher
Oct 21, 2026

United Therapeutics CEO Martine Rothblatt sells $5.26m in stock - Investing.com

Oct 21, 2026
pulisher
Oct 21, 2026

CEO trusts sell 9,500 United Therapeutics (UTHR) shares after exercising stock options. - Stock Titan

Oct 21, 2026
pulisher
Oct 21, 2026

United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026 - Yahoo Finance

Oct 21, 2026
pulisher
Oct 20, 2026

Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 19 October - Investing.com Nigeria

Oct 20, 2026
pulisher
Oct 20, 2026

United Therapeutics CEO Rothblatt sells $5.16m in shares - Investing.com

Oct 20, 2026
pulisher
Oct 20, 2026

United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500? - Yahoo Finance

Oct 20, 2026
pulisher
Oct 20, 2026

United Therapeutics opens third xenograft production facility - Investing.com

Oct 20, 2026
pulisher
Oct 20, 2026

A Houston site is built to make pig kidneys and hearts for United Therapeutics’ organ program. - Stock Titan

Oct 20, 2026
pulisher
Oct 20, 2026

United Therapeutics opens xeno-organ facility in Generation Park, marking Houston's continued pharma growth - The Business Journals

Oct 20, 2026
pulisher
Oct 20, 2026

United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility - Yahoo Finance

Oct 20, 2026
pulisher
Oct 20, 2026

United Therapeutics chairperson & CEO sells $5.08m in shares By Investing.com - Investing.com Nigeria

Oct 20, 2026
pulisher
Oct 19, 2026

Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 16 October - Investing.com Nigeria

Oct 19, 2026
pulisher
Oct 19, 2026

After exercising options at $117.76, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan

Oct 19, 2026
pulisher
Oct 19, 2026

Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga

Oct 19, 2026
pulisher
Oct 19, 2026

Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga

Oct 19, 2026
pulisher
Oct 19, 2026

United Therapeutics (UTHR) Gains FDA Approval for SUMMIT Trial o - GuruFocus

Oct 19, 2026
pulisher
Oct 19, 2026

Up to 800,000 people have high blood pressure in the lungs linked to chronic lung disease. An inhaler trial can proceed. - Stock Titan

Oct 19, 2026
pulisher
Oct 19, 2026

United Therapeutics (NASDAQ:UTHR): A GARP Case Built on Durable Growth at a Reasonable Price - ChartMill

Oct 19, 2026
pulisher
Oct 17, 2026

United Therapeutics chairperson & CEO sells $5.19m in stock - Investing.com

Oct 17, 2026
pulisher
Oct 16, 2026

Paul Mahon, United Therapeutics EVP, sells $4.5m in stock - Investing.com

Oct 16, 2026
pulisher
Oct 16, 2026

After exercising options at $117.76 each, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan

Oct 16, 2026
pulisher
Oct 16, 2026

An 8,300-share planned sale follows an option exercise by United Therapeutics (UTHR) counsel. - Stock Titan

Oct 16, 2026
pulisher
Oct 15, 2026

United Therapeutics CEO Rothblatt sells $5.1m in shares By Investing.com - Investing.com Nigeria

Oct 15, 2026
pulisher
Oct 15, 2026

After exercising options at $117.76, United Therapeutics (UTHR) CEO family trusts sell 9,500 shares. - Stock Titan

Oct 15, 2026
pulisher
Oct 14, 2026

A CEO trust exercises options at $117.76 and sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan

Oct 14, 2026
pulisher
Oct 14, 2026

United Therapeutics secures $381M settlement in patent dispute with competitor - The Business Journals

Oct 14, 2026
pulisher
Oct 14, 2026

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research

Oct 14, 2026
pulisher
Oct 14, 2026

Liquidia shares surge 25% as settlement ends United Therapeutics litigation - Yahoo Finance

Oct 14, 2026
pulisher
Oct 14, 2026

SGIOY or UTHR: Which Is the Better Value Stock Right Now? - Zacks Investment Research

Oct 14, 2026

United Therapeutics Corp (UTHR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

United Therapeutics Corp (UTHR) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
ROTHBLATT MARTINE A
Chairperson & CEO
Oct 27 '26
Sale
587.73
9,500
5,583,418
324,443
ROTHBLATT MARTINE A
Chairperson & CEO
Oct 26 '26
Sale
588.64
9,500
5,592,095
324,443
ROTHBLATT MARTINE A
Chairperson & CEO
Oct 26 '26
Option Exercise
117.76
9,500
1,118,720
333,943
ROTHBLATT MARTINE A
Chairperson & CEO
Oct 23 '26
Option Exercise
117.76
9,500
1,118,720
333,943
ROTHBLATT MARTINE A
Chairperson & CEO
Oct 23 '26
Sale
582.76
9,500
5,536,235
324,443
ROTHBLATT MARTINE A
Chairperson & CEO
Oct 22 '26
Option Exercise
117.76
9,500
1,118,720
333,943
ROTHBLATT MARTINE A
Chairperson & CEO
Oct 22 '26
Sale
583.38
9,500
5,542,094
324,443
ROTHBLATT MARTINE A
Chairperson & CEO
Oct 21 '26
Sale
560.07
9,500
5,320,681
324,443
ROTHBLATT MARTINE A
Chairperson & CEO
Oct 21 '26
Option Exercise
117.76
9,500
1,118,720
333,943
ROTHBLATT MARTINE A
Chairperson & CEO
Oct 20 '26
Sale
553.87
9,500
5,261,741
324,443
$18.77
price up icon 0.27%
ZTS ZTS
$77.80
price down icon 0.55%
$145.53
price down icon 0.32%
RDY RDY
$14.15
price up icon 2.91%
$22.65
price up icon 0.00%
$45.25
price up icon 2.10%
大文字化:     |  ボリューム (24 時間):